Theravance Biopharma, Inc. (NASDAQ:TBPH) Shares Purchased by Zurcher Kantonalbank Zurich Cantonalbank

Zurcher Kantonalbank Zurich Cantonalbank raised its holdings in shares of Theravance Biopharma, Inc. (NASDAQ:TBPH) by 31.4% in the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 9,330 shares of the biopharmaceutical company’s stock after buying an additional 2,227 shares during the quarter. Zurcher Kantonalbank Zurich Cantonalbank’s holdings in Theravance Biopharma were worth $105,000 as of its most recent SEC filing.

Other large investors have also modified their holdings of the company. Principal Financial Group Inc. grew its stake in Theravance Biopharma by 10.5% during the 3rd quarter. Principal Financial Group Inc. now owns 18,637 shares of the biopharmaceutical company’s stock valued at $161,000 after acquiring an additional 1,764 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. grew its position in shares of Theravance Biopharma by 4.7% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 44,532 shares of the biopharmaceutical company’s stock valued at $384,000 after purchasing an additional 1,993 shares in the last quarter. China Universal Asset Management Co. Ltd. increased its holdings in shares of Theravance Biopharma by 324.4% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 5,759 shares of the biopharmaceutical company’s stock valued at $65,000 after purchasing an additional 4,402 shares during the last quarter. Simplicity Solutions LLC purchased a new position in Theravance Biopharma during the fourth quarter worth approximately $141,000. Finally, Bleakley Financial Group LLC purchased a new stake in Theravance Biopharma in the 4th quarter valued at $141,000. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, BTIG Research started coverage on shares of Theravance Biopharma in a research report on Friday, April 12th. They set a “buy” rating and a $21.00 price target on the stock.

Theravance Biopharma Trading Down 0.2 %

NASDAQ TBPH opened at $9.47 on Friday. The stock has a market cap of $459.86 million, a PE ratio of -9.76 and a beta of 0.36. Theravance Biopharma, Inc. has a twelve month low of $8.21 and a twelve month high of $11.71. The stock has a fifty day simple moving average of $9.10 and a 200-day simple moving average of $9.68.

Theravance Biopharma (NASDAQ:TBPH) last announced its quarterly earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.02). Theravance Biopharma had a negative net margin of 96.12% and a negative return on equity of 19.31%. The company had revenue of $17.57 million for the quarter, compared to analyst estimates of $17.49 million. Research analysts predict that Theravance Biopharma, Inc. will post -0.84 EPS for the current year.

Theravance Biopharma Profile

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.